There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tricida (TCDA – Research Report) and Athira Pharma (ATHA – Research Report) with bullish sentiments.
Tricida (TCDA)
Needham analyst Serge Belanger maintained a Buy rating on Tricida today and set a price target of $18.00. The company’s shares closed last Monday at $10.80.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tricida with a $15.33 average price target, a 41.7% upside from current levels. In a report released today, Goldman Sachs also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Athira Pharma (ATHA)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Athira Pharma, with a price target of $6.00. The company’s shares closed last Monday at $3.81, close to its 52-week low of $2.53.
According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of
Athira Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $13.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TCDA:
- Analysts Offer Insights on Technology Companies: Asure (ASUR), MagnaChip (MX) and CarGurus (CARG)
- Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update
- SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2022
- Business Insurance Names CorVel’s CogencyIQ an Innovation of the Year
- Kaltura Announces Financial Results for Second Quarter 2022
